Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients

Autor: Ashok Kondur, Damon E. Houghton, Jalaj Garg, Rahul Chaudhary, M. Hassan Murad, Robert D. McBane, Waldemar E. Wysokinski, Rohit Chaudhary
Jazyk: angličtina
Rok vydání: 2021
Předmět:
medicine.medical_specialty
Medicine (General)
COPD
Chronic obstructive pulmonary disease
030204 cardiovascular system & hematology
Malignancy
Article
thrombo-inflammation
03 medical and health sciences
0302 clinical medicine
R5-920
CVD
Cardiovascular disease
ACE2
Angiotensin-converting enzyme 2
Diabetes mellitus
Internal medicine
ARDS
Acute respiratory distress syndrome
DIC
Disseminated intravascular coagulation
Medicine
030212 general & internal medicine
IL-6
Interleukin-6
PIC
Pulmonary intravascular coagulopathy
thrombosis
RT-PCR
Reverse transcription-polymerase chain reaction
COPD
biology
business.industry
WMD
Weighted mean difference
C-reactive protein
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement
COVID-19
biomarkers
Odds ratio
medicine.disease
Thrombosis
meta-analysis
CKD
Chronic kidney disease
hs-CRP
high-sensitivity C-reactive protein
inflammation
ECMO
Extracorporeal membrane oxygenation
Meta-analysis
CRP
C-reactive protein
biology.protein
business
Kidney disease
Zdroj: Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 2, Pp 388-402 (2021)
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
ISSN: 2542-4548
Popis: Objective: To evaluate differences in thromboinflammatory biomarkers between patients with severe coronavirus disease 2019 (COVID-19) infection/death and mild infection. Patients and Methods: MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, EBSCO, Web of Science, and CINAHL databases were searched for studies comparing thromboinflammatory biomarkers in COVID-19 among patients with severe COVID-19 disease or death (severe/nonsurvivors) and those with nonsevere disease or survivors (nonsevere/survivors) from January 1, 2020, through July 11, 2020. Inclusion criteria were (1) hospitalized patients 18 years or older comparing severe/nonsurvivors vs nonsevere/survivors and (2) biomarkers of inflammation and/or thrombosis. A random-effects model was used to estimate the weighted mean difference (WMD) between the 2 groups of COVID-19 severity. Results: We included 75 studies with 17,052 patients. The severe/nonsurvivor group was older, had a greater proportion of men, and had a higher prevalence of hypertension, diabetes, cardiac or cerebrovascular disease, chronic kidney disease, malignancy, and chronic obstructive pulmonary disease. Thromboinflammatory biomarkers were significantly higher in patients with severe disease, including D-dimer (WMD, 0.60; 95% CI, 0.49 to 0.71; I2=83.85%), fibrinogen (WMD, 0.42; 95% CI, 0.18 to 0.67; I2=61.88%; P 25%). Subanalysis based on disease severity, mortality, and geographic region of the studies revealed similar inferences. Conclusion: Thromboinflammatory biomarkers (D-dimer, fibrinogen, CRP, high-sensitivity CRP, ferritin, and interleukin 6) and marker of end-organ damage (high-sensitivity troponin I) are associated with increased severity and mortality in COVID-19 infection.
Databáze: OpenAIRE
Externí odkaz: